If You Invested in Sunshine Biopharma Inc (SBFM)

Sunshine Biopharma Inc. (NASDAQ: SBFM) is a pharmaceutical and biotechnology company engaged in research and development in biotechnology and the commercialization of prescription medicines. According to company disclosures, Sunshine Biopharma focuses on life-saving and life-enhancing medicines in therapeutic areas that include oncology, antivirals, infectious diseases, metabolic and cardiovascular disorders, and gastrointestinal conditions. The company operates in the Professional, Scientific, and Technical Services sector and is incorporated in Colorado. Its common stock and common stock purchase warrants (SBFMW) trade on The Nasdaq Stock Market LLC.

Sunshine Biopharma’s business model combines a commercial generics and biosimilars platform with an internal proprietary drug development program. Through its wholly owned Canadian subsidiary Nora Pharma Inc., the company markets a large catalog of generic prescription drugs in Canada. Company materials state that Sunshine Biopharma has over 70 generic prescription drugs on the Canadian market, with additional launches planned. These products span therapeutic classes such as anticonvulsants, antibiotics, lipid metabolism regulators, and gastrointestinal agents, providing recurring revenue from pharmacies, hospitals, and healthcare providers across Canada.

Commercial Generics and Biosimilars

Nora Pharma is described as Sunshine Biopharma’s commercial arm in Canada, focused on generic pharmaceuticals and, more recently, biosimilars. The subsidiary has launched multiple generic drugs, including:

• Gabapentin, a generic version of Neurontin in the anticonvulsant class, used for neuropathic pain, epilepsy, and pain associated with conditions such as diabetic neuropathy, central pain, and postherpetic neuralgia. Nora Pharma supplies gabapentin in capsule format in several strengths, emphasizing ease of administration.
• Doxycycline, a broad-spectrum antibiotic used in the treatment of respiratory tract infections, urinary tract infections, sexually transmitted diseases, acne, and tick-borne illnesses such as Lyme disease. The product is distributed to pharmacies, hospitals, and healthcare providers across Canada.
• Pravastatin, a generic version of Pravachol in the lipid metabolism regulator class. Pravastatin is a statin medication used to lower LDL (“bad”) cholesterol and increase HDL (“good”) cholesterol to help reduce the risk of heart attacks, strokes, and other cardiovascular conditions.
• Domperidone, a prescription medication used to relieve nausea and vomiting and to enhance gastrointestinal motility. Health Canada has authorized Nora Pharma to commercialize domperidone in Canada, including for chemotherapy-induced nausea and vomiting, particularly where patients cannot tolerate other antiemetics that may cause extrapyramidal side effects.

Beyond traditional generics, Sunshine Biopharma has entered the biosimilars space. Nora Pharma launched NIOPEG®, described as the company’s first biosimilar drug on the market. NIOPEG is a biosimilar comparable to the reference biologic NEULASTA® (pegfilgrastim), a long-acting, pegylated form of recombinant human granulocyte colony-stimulating factor (filgrastim). Like its reference product, NIOPEG is indicated to decrease the incidence of infection in patients with non-myeloid malignancies receiving chemotherapy. By offering a biosimilar alternative, Sunshine Biopharma positions itself in the high-value biologics segment while maintaining a focus on oncology-related supportive care.

Proprietary Drug Development Programs

In addition to its generics and biosimilars portfolio, Sunshine Biopharma is conducting a proprietary drug development program centered on oncology and antiviral research. Company disclosures describe two primary development assets:

• K1.1 mRNA: an mRNA–lipid nanoparticle therapy targeted for liver cancer. Sunshine Biopharma reports that K1.1 is an mRNA-based therapy that has shown measurable tumor reduction in liver cancer models with tolerability in preclinical experiments. This program reflects the company’s participation in mRNA-based oncology research.
• PLpro protease inhibitor program: a small-molecule antiviral initiative aimed at the treatment of SARS coronavirus infections. Working in collaboration with the University of Arizona, Sunshine Biopharma has developed orally active, non-covalent PLpro protease inhibitors that exhibit dose-dependent antiviral activity in animal and cellular models of SARS-CoV-2 infection. The company reports that its lead compounds have demonstrated favorable pharmacokinetics and efficacy in transgenic mouse models, and that a second novel chemical series of PLpro inhibitors has been designed and synthesized with potent activity against the PLpro enzyme and dose-dependent efficacy in cellular models.

These proprietary programs are intended to address unmet medical needs in liver cancer and coronavirus infections by targeting disease mechanisms such as tumor growth and viral protease activity associated with replication and immune evasion.

Therapeutic Focus and Market Context

Across its operations, Sunshine Biopharma emphasizes oncology, antiviral therapies, infectious diseases, cardiovascular health, and gastrointestinal disorders. Its generics portfolio includes products for neuropathic pain and epilepsy (gabapentin), bacterial infections (doxycycline), cholesterol management (pravastatin), and chemotherapy-related nausea and vomiting (domperidone). Its biosimilar NIOPEG addresses infection risk in cancer patients receiving chemotherapy.

In antiviral research, Sunshine Biopharma’s PLpro inhibitor program targets SARS-CoV-2 and related coronaviruses by focusing on the PLpro enzyme, which is described as essential for viral replication and involved in suppression of the human immune system following infection. The company has reported publication of initial research results on its PLpro inhibitor library in a peer-reviewed journal, followed by the development of a second series of orally active compounds with favorable pharmacokinetics in mice.

Corporate and Regulatory Information

Sunshine Biopharma Inc. is incorporated in Colorado and files periodic and current reports with the U.S. Securities and Exchange Commission (SEC). Recent SEC filings include Form 8-K reports and a Definitive Proxy Statement on Schedule 14A. The company’s proxy materials describe matters such as the election of directors, ratification of its independent registered public accounting firm, and amendments to its equity incentive plan. A Form 8-K filed in September 2025 reports a change in the company’s independent registered public accounting firm, with M&K CPAS, PLLC engaged as auditor following the dismissal of Bush & Associates CPA LLC. Another Form 8-K filed in December 2025 reports the results of the annual meeting of stockholders, including the election of directors, ratification of M&K CPAS, PLLC as independent registered public accounting firm for 2025, and approval of an amendment to the 2023 Equity Incentive Plan.

The company has also disclosed a treasury strategy involving digital assets. Sunshine Biopharma announced that its board of directors approved an allocation of $5 million for investment in Bitcoin (BTC) as a strategic reserve asset. The investment is to be executed over time through a regulated digital asset custodian or via an exchange-traded fund or proxy stock, with the company indicating that it may increase its Bitcoin holdings as funds become available. This initiative is described as part of a broader strategy to strengthen the company’s financial foundation while it advances its generic drug portfolio and proprietary mRNA-based cancer therapies and antiviral candidates.

Business Scale and Positioning

Company communications describe Sunshine Biopharma as a microcap biotech and pharmaceutical company that combines revenue from a growing generics and biosimilars portfolio with longer-term value from proprietary drug development. Nora Pharma’s generics catalog in Canada, including more than 70 marketed prescription drugs and additional planned launches, is presented as a base of recurring revenue and regulatory credibility. The launch of NIOPEG as a biosimilar to a widely used oncology biologic is highlighted as a step into complex biologics, while the K1.1 mRNA and PLpro inhibitor programs represent the company’s research and development activities in oncology and antiviral therapeutics.

According to company descriptions, this combination of commercial operations and R&D is intended to create a model in which revenue-generating products support the advancement of higher-risk, higher-potential drug candidates. Sunshine Biopharma’s activities span generic pharmaceuticals, biosimilars, mRNA-based oncology research, and small-molecule antiviral development, all within the broader biotechnology and pharmaceutical industry.